Parenteral colloidal iron-complex preparations;Parenterale kolloidale eisenkomplexpräparate

Deutsche Apotheker Zeitung

Volumn 146, Issue 14, 2006, Pages 62-71

  Jahn, Markus ^a   Roth, Susanne ^a   Langguth, Peter ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

DEXTRAN; ERYTHROPOIETIN; FERRIC HYDROXIDE; GLUCONIC ACID; IRON COMPLEX; MYOGLOBIN; SUCROSE;

ANAPHYLAXIS; HEMODIALYSIS; HUMAN; IRON DEFICIENCY; RETICULOENDOTHELIAL SYSTEM; REVIEW; RISK FACTOR;

EID: 33646246606     PISSN: 00119857     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (72)

1. Scheiber-Mojdehkar B, et al: Influence of parenteral iron preparations on non-transferrin bound iron uptake, the iron regulatory protein and the expression of ferritin and the divalent metal transporter DMT-1 in HepG2 human hepatoma cells. Biochem Pharmacol 2003;65 (12):1973-8.
2. Andrews NC: Iron homeostasis: insights from genetics and animal models. Nat Rev Genet 2001;1 (3):208-17.
3. Locatelli F, et al: Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant 2004;19 (Suppl 2):1-47.
4. Chertow GM, et al: On the relative safety of parenteral iron formulations. Nephrol Dial Transplant 2004;19 (6):1571-5.
5. Kosch M. et al: A randomized, controlled parallel-group trial on efficacy and safety of iron sucrose (Venofer) vs iron gluconate (Ferrlecit) in haemodialysis patients treated with rHuEpo. Nephrol Dial Transplant 2001;16 (6):1239-44.
6. Heinrich H: Bioverfügbarkeit und therapeutischer Wert oraler Eisen(II)- und Eisen(III)-Präparate. Dtsch Apoth Ztg 1986;14:681-690.
7. Macdougall IC: Strategics for iron supplementation: oral versus intravenous. Kidney Int Suppl 1999;69:61-6.
8. Gry-Pharma: Fachinformation CosmoFer®. 2003.
9. Besarab A, et al: Optimization of epoetin therapy with intravenous iron therapy in hemodialysis patients. J Am Soc Nephrol 2000;11 (3):530-8.
10. Kudasheva DS, et al: Structure of carbohydrate-bound polynuclear iron oxyhydroxide nanoparticles in parenteral formulations. J Inorg Biochem 2004;98 (11):1757-69.
11. Cox JSG, et al: Structure of an iron-dextran complex. J Pharm Pharmacol 1972;24 (7):513-17.
12. London GM: The molecular formula and proposed structure of the iron-dextran complex, IMFERON. J Pharm Sci 2004;93 (7):1838-1846.
13. Lawrence R: Development and comparison of iron dextran products. PDA J Pharm Sci Technol 1998;52 (5):190-7.
14. Beshara S, et al: Pharmacokinetics and red cell utilization of iron(III) hydroxide-sucrose complex in anaemic patients: a study using positron emission tomography. Br J Haematol 1999;104 (2):296-302.
15. Afzali B, Goldsmith DJ: Intravenous iron therapy in renal failure: friend and foe? J Nephrol 2004;17 (4):487-95.
16. Fletes R, et al: Suspected iron dextran-related adverse drug events in hemodialysis patients. Am J Kidney Dis 2001;37 (4):743-9.
17. Michael B, et al: Sodium ferric gluconate complex in hemodialysis patients: adverse reactions compared to placebo and iron dextran. Kidney Int 2002;61 (5):1830-9.
18. Fishbane S, et al: The safety of intravenous iron dextran in hemodialysis patients. Am J Kidney Dis 1996;28 (4):529-34.
19. Chertow GM, et al: On the relative safety of parenteral iron formulations. Nephrol Dial Transplant 2004; 19(6):1571-5.
20. Kruszewski M; The role of labile iron pool in cardiovascular diseases. Acta Biochim Pol 2004;51 (2):471-80.
21. Esposito BP, et al: Labile iron in parenteral iron formulations and its potential for generating plasma nontransferrin-bound iron in dialysis patients. Eur J Clin Invest 2002;32 (Suppl 1):42-9.
22. Van Wyck DB: Labile iron: manifestations and clinical implications. J Am Soc Nephrol 2004;15 (Suppl 2):107-11.
23. Geisser P, Baer M, Schaub E: Structure/histotoxicity relationship of parenteral iron preparations. Arzneimittelforschung 1992;42 (12):1439-52.
24. Van Wyck D, Anderson J, Johnson K: Labile iron in parenteral iron formulations: a quantitative and comparative study. Nephrol Dial Transplant 2004;19 (3):561-5.
25. Agarwal R: Transferrin saturation with intravenous irons: an in vitro study. Kidney Int 2004;66 (3):1139-44.
26. Lewis JM, Jacobs PM, Frigo TB: Comparison of free iron in Ferumoxytol with current iron therapeutics. J Am Soc Nephrol 2003:14.
27. Esposito BP, et al: Labile plasma iron in iron overload: redox activity and susceptibility to chelation. Blood 2003;102 (7):2670-7.
28. Sturm B, et al: Transient increase of the labile iron pool in HepG2 cells by intravenous iron preparations. Eur J Biochem 2003;270 (18):3731-8.
29. Langguth, P. Iron Complex formulations for parenteral administration differ in terms of stability and release rate in serum. 2003. Würzburg. (Conference Proceeding)
30. Sies H: Oxidative stress: oxidants and antioxidants. Exp Physiol 1997;82 (2):291-5.
31. Locatelli F, et al: Oxidative stress in end-stage renal disease: an emerging threat to patient outcome. Nephrol Dial Transplant 2003;18 (7):1272-80.
32. Salahudeen AK, et al: Increase in plasma esterified F2-isoprostanes following intravenous iron infusion in patients on hemodialysis. Kidney Int 2001;60 (4):1525-31.
33. Michelis R, et al: Carbonyl stress induced by intravenous iron during haemodialysis. Nephrol Dial Transplant 2003;18 (5): 924-30.
34. Lim PS, et al: Enhanced oxidative stress in haemodialysis patients receiving intravenous iron therapy. Nephrol Dial Transplant 1999;14 (11):2680-7.
35. Parkkinen J, et al: Catalytically active iron and bacterial growth in scrum of haemodialysis patients after i.V. iron-saccharate administration. Nephrol Dial Transplant 2000;15 (11):1827-34.
36. Drueke T, et al: Iron therapy, advanced oxidation protein products, and carotid artery intima-media thickness in end-stage renal disease. Circulation 2002;106 (17):2212-7.
37. Sengoelge G, et al: Dose-dependent effect of parenteral iron therapy on bleomycin-detectable iron in immune apheresis patients. Kidney Int 2004;66 (1):295-302.
38. Roob JM, et al: Vitamin E attenuates oxidative stress induced by intravenous iron in patients on hemodialysis. J Am Soc Nephrol 2000;11 (3):539-49.
39. Tovbin D, et al: Induction of protein oxidation by intravenous iron in hemodialysis patients: role of inflammation. Am J Kidney Dis 2002;40 (5):1005-12.
40. Leehey DJ, et al: Sodium ferric gluconate causes oxidative stress but not acute renal injury in patients with chronic kidney disease: a pilot study. Nephrol Dial Transplant 2005;20 (1):135-40.
41. Zager RA, et al: Parenteral iron formulations: a comparative toxicologic analysis and mechanisms of cell injury. Am J Kidney Dis 2002;40 (1):90-103.
42. Zager RA, et al: Parenteral iron compounds sensitive mice to injury-initiated TNF-alpha mRNA production and TNF-alpha release. Am J Physiol Renal Physiol 2005;288 (2):290-7.
43. Zager RA: Parenteral iron treatment induces MCP-1 accumulation in plasma, normal kidneys, and in experimental nephropathy. Kidney Int 2005;68 (4):1533-42.
44. Zager RA. Johnson AC, Hanson SY: Parenteral iron nephrotoxicity: potential mechanisms and consequences. Kidney Int 2004;66 (1):144-56.
45. Agarwal R, et al: Oxidative stress and renal injury with intravenous iron in patients with chronic kidney disease. Kidney Int 2004; 65(6):2279-89.
46. Sato K, et al: Saccharated ferric oxide (SFO)-induced osteomalacia: in vitro inhibition by SFO of bone formation and 1,25-dihydroxy-vitamin D production in renal tubules. Bone 1997;21 (1):57-64.
47. Flament J, et al: Impairment of phagocyte oxidative metabolism in hemodialyzed patients with iron overload. Clin Nephrol 1986;25 (5):227-30.
48. Vanholder R, Ringoir S: Infectious morbidity and defects of phagocytic function in end-stage renal disease: a review. J Am Soc Nephrol 1993;3 (9):1541-54.
49. Guo D, et al: Impact of iron dextran on polymorphonuclear cell function among hemodialysis patients. Clin Nephrol 2002;58 (2):134-42.
50. Patruta SI, et al: Neutrophil impairment associated with iron therapy in hemodialysis patients with functional iron deficiency. J Am Soc Nephrol 1998;9 (4):655-63.
51. Deicher R, et al: High-dose parenteral iron sucrose depresses neutrophil intracellular killing capacity. Kidney Int 2003;64 (2):728-36.
52. Hoen B, et al: EPIBACDIAL: a multicenter prospective study of risk factors for bacteremia in chronic hemodialysis patients. J Am Soc Nephrol 1998;9 (5):869-76.
53. Boelaert JR, et al: Iron overload in haemodialysis patients increases the risk of bacteraemia: a prospective study. Nephrol Dial Transplant 1990;5 (2):130-4.
54. Tielemans CL, et al: Critical role of iron overload in the increased susceptibility of haemodialysis patients to bacterial infections. Beneficial effects of desferrioxamine. Nephrol Dial Transplant 1989;4 (10):883-7.
55. Hoen B. et al: Risk factors for bacterial infections in chronic haemodialysis adult patients: a multicentre prospective survey. Nephrol Dial Transplant 1995;10 (3):377-81.
56. Bullen JJ, et al: Iron and infection: the heart of the matter. FEMS Immunol Med Microbiol 2005;43 (3):325-30.
57. Mazmanian SK, et al: Passage of heme-iron across the envelope of Staphylococcus aureus. Science 2003;299 (5608): 906-9.
58. Locatelli F, et al: Cardiovascular disease in chronic renal failure: the challenge continues. Registro Lombardo Dialisi e Trapianto. Nephrol Dial Transplant 2000;15 (Suppl 5):69-80.
59. Shah SV, Alam MG: Role of iron in atherosclerosis. Am J Kidney Dis 2003;41 (Suppl 1):80-3.
60. Sullivan JL: Iron and the sex difference in heart disease risk. Lancet 1981;1 (8233):1293-4.
61. Salonen JT, et al: High stored iron levels are associated with excess risk of myocardial infarction in eastern Finnish men. Circulation 1992;86 (3):803-11.
62. Kiechl S, et al: Body iron stores and the risk of carotid atherosclerosis: prospective results from the Bruneck study. Circulation 1997;96 (10):3300-7.
63. Klipstein-Grobusch K. et al: Serum ferritin and risk of myocardial infarction in the elderly: the Rotterdam Study. Am J Clin Nutr 1999;69 (6):1231-6.
64. Duffy SJ, et al: Iron chelation improves endothelial function in patients with coronary artery disease. Circulation 2001;103 (23):2799-804.
65. Danesh J, Appleby P: Coronary heart disease and iron status: meta-analyses of prospective studies. Circulation 1999;99 (7):852-4.
66. Franco RF, et al: Prevalence of hereditary haemochromatosis in premature atherosclerotic vascular disease. Br J Haematol 1998;102 (5):1172-5.
67. Baer DM, Tekawa IS, Hurley LB: Iron stores are not associated with acute myocardial infarction. Circulation 1994;89 (6):2915-8.
68. Kirk EA, Heinecke JW, LeBoeuf RC: Iron overload diminishes atherosclerosis in apoE-deftcient mice. J Clin Invest 2001;107 (12):1545-53.
69. Lee TS, et al: Iron-deficient diet reduces atherosclerotic lesions in apoE-deficiem mice. Circulation 1999;99 (9): 1222-9.
70. Feldman HI, et al: Administration of parenteral iron and mortality among hemodialysis patients. J Am Soc Nephrol 2004;15 (6):1623-32.
71. Centers for Disease Control and Prevention. Normal Iron Absorption and Metabolism. (Electronic Citation)
72. Danielson BG: Structure, chemistry, and pharmacokinetics of intravenous iron agents. J Am Soc Nephrol 2004;15 Suppl 2: 93-8.